0000001800 false Common Shares, Without Par Value ABT 0000001800 2020-04-23 2020-04-24 0000001800 us-gaap:CommonStockMember exch:XCHI 2020-04-23 2020-04-24 0000001800 us-gaap:CommonStockMember exch:XNYS 2020-04-23 2020-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
   

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

April 24, 2020

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

 

Illinois   1-2189   36-0698440
(State or other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

 

 

100 Abbott Park Road

Abbott Park,Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading 

Symbol(s)

Name of Each Exchange on

Which Registered

Common Shares, Without Par Value ABT New York Stock Exchange

Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 5.07 — Submission of Matters to a Vote of Security Holders.

 

Abbott held its Annual Meeting of Shareholders on April 24, 2020. The following is a summary of the matters voted on at that meeting.

 

(1)The shareholders elected Abbott’s entire Board of Directors. The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number of shares withheld, and the number of broker non-votes, with respect to each of these persons, were as follows:

 

Name  Votes For   Votes Withheld   Broker Non-Votes 
Robert J. Alpern, M.D.   1,339,883,794    17,727,527    205,521,308 
Roxanne S. Austin   1,288,595,809    69,015,512    205,521,308 
Sally E. Blount, Ph.D.   1,353,893,667    3,717,654    205,521,308 
Robert B. Ford   1,343,514,772    14,096,550    205,521,308 
Michelle A. Kumbier   1,343,669,496    13,941,825    205,521,308 
Edward M. Liddy   1,333,732,689    23,878,632    205,521,308 
Darren W. McDew   1,352,315,607    5,295,714    205,521,308 
Nancy McKinstry   1,067,064,716    290,546,605    205,521,308 
Phebe N. Novakovic   1,341,182,943    16,428,379    205,521,308 
William A. Osborn   1,323,132,704    34,478,618    205,521,308 
Daniel J. Starks   1,340,794,056    16,817,265    205,521,308 
John G. Stratton   1,353,108,028    4,503,294    205,521,308 
Glenn F. Tilton   1,296,859,378    60,751,943    205,521,308 
Miles D. White   1,321,600,922    36,010,399    205,521,308 

 

(2)The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
 1,550,970,892    9,518,284    2,643,453    0 

 

(3)The shareholders voted to approve the compensation of Abbott’s named executive officers listed in the proxy statement for the 2020 annual meeting, with 92.01 percent of the votes cast voting “For” the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
 1,249,119,989    100,298,672    8,192,660    205,521,308 

 

 

 

 

(4)The shareholders rejected a shareholder proposal that Abbott’s Board of Directors prepare a report, to be updated annually, disclosing Abbott’s lobbying policies, procedures, and expenditures, with 19.68 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
 267,208,881    1,082,456,479    7,945,960    205,521,308 

 

(5)The shareholders rejected a shareholder proposal requesting that Abbott provide certain proxy disclosure regarding adjustments to GAAP financial performance metrics, with 30.76 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
 417,543,155    931,644,755    8,423,410    205,521,308 

 

(6)The shareholders rejected a shareholder proposal requesting that any Board approved By-Law amendment be subject to a non-binding shareholder vote, with 2.38 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
 32,263,098    1,317,026,280    8,321,942    205,521,308 

 

(7)The shareholders passed a shareholder proposal regarding simple majority vote, with 84.48 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
 1,146,927,037    204,066,841    6,617,443    205,521,308 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBOTT LABORATORIES
   
     
Date: April 28, 2020 By:  /s/ Robert E. Funck, Jr.
    Robert E. Funck, Jr.
    Executive Vice President, Finance
    and Chief Financial Officer